Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- S&P 500, Dow slide after jobs report fuels rate-hike bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil heads for weekly gain as US-Iran fighting resumes; diesel hits record high
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Myriad Genetics (MYGN) Tops Q4 EPS by 5c; Raises Outlook
August 21, 2018 4:08 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.38, $0.05 better than the analyst estimate of $0.33. Revenue for the quarter came in at $200.9 million versus the consensus estimate of $195.76 million.
GUIDANCE:
Myriad Genetics sees Q1 2019 EPS of $0.28-$0.30, versus the consensus of... More
